REFERENCES
- PaleIla FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
- Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 1998;352:1725–1730.
- Adkins JC, Noble S. Efavirenz. Drugs. 1998;56:1055–1064.
- Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2001345: 398–407.
- Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS. 2001;15:1679–1686.
- Moyle GJ. Efavirenz: shifting the HAART paradigm in adult HIV-1 infection. Exp Opin Invest Drugs. 1999;8:473–486.
- Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15:1369–1377.
- Rachlis A, Becker S, Gill J, et al. Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads-a prospective, randomized, multicenter, open-label study (DMP 049). In: Program and abstracts of the First International AIDS Society Confer-ence on HIV Pathogenesis and Treatment; July 8–11, 2001; Buenos Aires, Argentina. Abstract 812.
- Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865–1873.
- Tashima K, Staszewski S, Morales-Ramirez J, et al. 3-year durability of response with an efavirenz (EFV)-containing regimen: 144-week follow-up of Study 006. In: Program and abstracts of the First International AIDS Society Con-ference on HIV Pathogenesis and Treatment; July 8–11, 2001; Buenos Aires, Argentina. Abstract 810.
- Vigilancia epidemiológica del VIH/SIDA (31 de diciembre de 1999). Boletín Epidemiológico de la Comunidad de Madrid. 2000;6(8):3–61.
- Carpenter CJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. Updated recommendations of the Inter-national AIDS Society-USA Panel. JAMA. 2000;283:381–390.
- Department of Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adoles-cents. 2001. www.hivatis.org.
- Shafran SD, Lefevre E, Baril JG, Cornelson B, Walmsley SL, Fang IW. Retrospective analysis of factors associated with discontinuation of efavirenz (EFV) due to adverse ef-fects (AEs). Paper presented at: 5th International Congress on Drug Therapy in HIV Infection; October 22–26, 2000; Glasgow, UK.
- Manion DJ, Koziak KZ, Block DS, Montgomery WC, Jo-seph JL, Bessen U. Efavirenz expanded access program: North American experience. Paper presented at: 5th Inter-national Congress on Drug Therapy in HIV Infection; Octo-ber 22–26, 2000; Glasgow, UK.
- Gregoire V, Mariot P. Efficacy and safety of sustiva (efavirenz) in the French TAU (Temporary Authorization for Use): A programme providing rapid access to drugs prior to registration. In: Program and abstracts of the 13th Inter-national AIDS Conference; July 9–14, 2000; Durban, South Africa. Abstract ThPeB5272.
- Dona C, Soriano V, Barreiro P, Jimenez-Nachera I, Gonzalez-Lahoz J. [Toxicity associated with efavirenz in HIV-infected persons enrolled in an expanded access pro-gram]. Med Clin (Barc). 2000;115:337–338.
- Blanch J, Martinez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr. 2001;27:336–343.
- Ficha técnica de Efavirenz. Stevenage, Hertfordshire: DuPont Pharmaceuticals Limited. Reino Unido; October 2000.
- Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differ-ences in nevirapine rash. Clin Infect Dis. 200132: 124–129.
- Knobel H, Codina C, Mitt JM, et al. Recomendaciones GESIDA/SEFH/PNS para mejorar la adherencia al tratamiento antirretroviral. Enferm Infecc Microbiol Cl/n. 2000;18:27–39.
- Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin In-fect Dis. 2000;30\(suppl 2):S96–S116.
- Clarke S, Harrington P, Barry M, Mulcahy F. The tolerability of efavirenz after nevirapine-related adverse events. Clin Infect Dis. 2000;31:806–807.